Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Finch Therapeutics Group Inc (NQ: FNCH )

0.5162 +0.0262 (+5.35%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 191,068
Open 0.5100
Bid (Size) 0.5000 (15)
Ask (Size) 0.5300 (9)
Prev. Close 0.4900
Today's Range 0.4900 - 0.5300
52wk Range 0.3001 - 9.280
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Finch Therapeutics Halts Work On Its Only Clinical Stage Asset, Cuts 95% Of Workforce
 
Via Benzinga

Performance

YTD
+13.65%
+13.65%
1 Month
+13.65%
+13.65%
3 Month
-58.70%
-58.70%
6 Month
-76.75%
-76.75%
1 Year
-94.00%
-94.00%

More News

Read More
Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets
From Finch Therapeutics Group, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial Results
From Finch Therapeutics Group, Inc.
Via Globe NewsWire
Finch Therapeutics to Present at the Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference
From Finch Therapeutics Group, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Finch Therapeutics Presents PRISM-EXT Biomarker Data at ACG 2022 and Proceeds with Patient Dosing in Phase 3 Trial of CP101 in Recurrent C. Difficile Infection
From Finch Therapeutics Group, Inc.
Via Globe NewsWire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Benzinga Before The Bell: Elon Musk's Demand For Broad Twitter Data Dismissed, Xiaomi Wants To Join EV Race, Bed Bath & Beyond Plans To Share Turnaround Strategy Next Week And Other Top Financial Stories Friday, August 26
Via Benzinga
After Six Years Of Collaboration, Takeda Walks Away From Microbiome Drug Pact
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2022
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Acurx Pharmaceuticals Is Under The Radar, That’s Excellent News For Investors Wanting Exposure To Billion Dollar CDI Treatment Market ($ACXP)
Via AB Newswire
Exposures Product Safety
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Stock Market Recap: This Week’s 5 Top Stories
Via InvestorPlace
70 Biggest Movers From Friday
Via Benzinga
Is ROKU Stock a Buy After Earnings? 4 Analysts Weigh In on Roku.
Via InvestorPlace
48 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Why Is Finch Therapeutics (FNCH) Stock Up 30% Today?
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.